Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing
Podcast Image

Lung Cancer Considered

Science

Episodes

Showing 101-200 of 387
«« ← Prev Page 2 of 4 Next → »»

IASLC Lung Cancer Considered in German

22 Jan 2025

Contributed by Lukas

Description: As part of IASLC’s commitment to communicating in all world languages, this episode of Lung Cancer Considered is recorded in German and...

FDA Approval Zenocutuzumab For NRG1 Fusion Cancers

21 Jan 2025

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG...

ESMO Immuno-Oncology Congress 2024 Highlights

13 Jan 2025

Contributed by Lukas

ESMO Immuno-Oncology Congress 2024 Highlights Description: In this episode of Lung Cancer Considered, host Dr. Narjust Florez and Dr. Alfredo Addeo...

2025 Pan-Africa Conference on Lung Cancer Meeting Preview

18 Dec 2024

Contributed by Lukas

Preview: 2025 Pan-Africa Lung Cancer Meeting The 2025 Pan-Africa Lung Cancer Conference will take place January 31 - February 1, 2025, in Accra, Ghan...

IASLC Lung Cancer Considered: ESMO Asia 2024 Highlights

16 Dec 2024

Contributed by Lukas

Lung Cancer Considered host Dr. Stephen Liu and two distinguished thoracic oncologists review the highlights from the recently completed ESMO Asia 202...

FDA Approval: TT Fields for NSCLC

13 Dec 2024

Contributed by Lukas

Tumor Treating Fields (TTFields) is a non-invasive cancer treatment that uses alternating electric fields to disrupt the ability of cancer cells to di...

FDA Approval: Perioperative Nivolumab + Chemotherapy - CheckMate 77T

12 Dec 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of perioperative nivolumab based on the Phase I...

LALCA Episode in English

03 Dec 2024

Contributed by Lukas

In this episode of Lung Cancer Considered host Dr. Narjust Florez discusses the future of lung cancer research in Brazil and the largest lung cancer s...

Lung Cancer Considered in German

02 Dec 2024

Contributed by Lukas

Lung Cancer Considered in German by IASLC

Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System

29 Nov 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests preview the publication of the Ninth Edition of Tumor, Node and Metastasis ...

LAURA Trial Part 1

29 Nov 2024

Contributed by Lukas

Lung Cancer Considered host Dr. Narjust Florez and Dr. Suresh Ramalingam discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR ...

LALCA Highlights in Spanish

29 Nov 2024

Contributed by Lukas

Description: Join us for an engaging discussion on groundbreaking research from investigators across Latin America, featuring insights from large lung...

Lung Cancer Considered--The Year in Review

26 Nov 2024

Contributed by Lukas

Lung cancer breakthroughs, practice updates, and key meetings made 2024 one of the most consequential years in recent memory for lung cancer researche...

Virtual Tumor Board_Metastatic Squamous NSCLC

13 Nov 2024

Contributed by Lukas

Description: In this virtual tumor board episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the management of a patient wit...

LCC in Hindi: Contemporary Issues in Lung Cancer Care

13 Nov 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, Dr. Aakash Desai moderates a discussion in Hindi on management of non-small cell lung cancer and small cell...

Virtual Tumor Board: Pregnancy

12 Nov 2024

Contributed by Lukas

Description: As the incidence of lung cancer in those under age 35 increases, oncologists are finding that pregnancy is a central issue for many young...

IASLC - Exercise And Lung Cancer

05 Nov 2024

Contributed by Lukas

The Power of Movement: Exercise and Lung Cancer-- a Conversation with Experts Description: In this episode of Lung Cancer Considered, host Dr. Narjus...

IASLC - Hot Topic Meeting On Tolerance And Resistance To Targeted Therapy In NSCLC 2

29 Oct 2024

Contributed by Lukas

Title: IASLC Hot Topic Meeting on Tolerance and Resistance to Targeted Therapy in NSCLC (recorded on 10/21) Description: In this episode of Lung Can...

LCC in Arabic: Training and Education in Medical Oncology and Lung Cancer

25 Oct 2024

Contributed by Lukas

As part of the IASLC's ongoing series of podcasts in world languages, this episode brings together two leading lung cancer experts who discuss trainin...

IASLC Virtual Tumor Board Relapsed SCLC

22 Oct 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a discussion about the management of relapsed SCLC, which remains a very cha...

Lung Cancer Considered--Managing ADC Toxicities

08 Oct 2024

Contributed by Lukas

Lung Cancer Considered--Managing ADC Toxicities by IASLC

LCC in Arabic: WCLC 2024 Highlights

27 Sep 2024

Contributed by Lukas

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung can...

IASLC LALCA Preview (in Spanish)

24 Sep 2024

Contributed by Lukas

Host Dr. Narjust Florez previews the 2024 Latin America Lung Cancer Meeting with co-chairs Dr. Lucia Viola, Dr. Andres Feliple Cardona and Dr. Stella ...

ESMO 2024 Highlights

20 Sep 2024

Contributed by Lukas

This episode of Lung Cancer Considered covers the recently completed 2024 ESMO Congress in Barcelona. Host Dr. Stephen Liu discussed the important res...

FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma

18 Sep 2024

Contributed by Lukas

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for...

IASLC - ACLC 2024 Preview

18 Sep 2024

Contributed by Lukas

In this episode of Lung Cancer Consider, host Dr. Stephen Liu previews the upcoming IASLC 2024 Asia Conference on Lung Cancer with meeting co-chair, D...

FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC

17 Sep 2024

Contributed by Lukas

Description: The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MA...

LCC in Portuguese: WCLC 2024 Highlights

12 Sep 2024

Contributed by Lukas

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung can...

Live From WCLC 2024: Nurse Practitioner Highlights

11 Sep 2024

Contributed by Lukas

In this special episode of Lung Cancer Considered, Stephanie McDonald and Jillian Thompson discuss their perspectives of attending the 2024 World Conf...

LCC in Spanish: WCLC 2024 Highlights

11 Sep 2024

Contributed by Lukas

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung can...

Live From WCLC 2024: Meeting Summary

11 Sep 2024

Contributed by Lukas

In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting...

LCC in Mandarin: WCLC 2024 Highlights

10 Sep 2024

Contributed by Lukas

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung can...

Live From WCLC 2024: Monday Highlights

09 Sep 2024

Contributed by Lukas

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference. Dr. Xiuning Le r...

LCC in Korean: WCLC 2024 Highlights

09 Sep 2024

Contributed by Lukas

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung can...

Live From WCLC 2024: Sunday Highlights

08 Sep 2024

Contributed by Lukas

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference. Dr. Caicun Zhou dis...

With Eyes On The Future IASLC 50th Anniversary

03 Sep 2024

Contributed by Lukas

Description: To celebrate IASLC’s 50th Anniversary, IASLC produced podcasts looking at our past and present. In this podcast, host Dr. Narjust Flor...

IASLC's 50th Anniversary: The IASLC Today

27 Aug 2024

Contributed by Lukas

Description: This year marks the 50th anniversary of the International Association for the Study of Lung Cancer and as part of this celebratory year, ...

IASLC - The First Decade

20 Aug 2024

Contributed by Lukas

In 1972, in response to the overwhelming need for collaboration and a growing concern for public health, Drs. David T. Carr, Oleg S. Selawry, Lawrence...

FDA Approval: MARIPOSA, First-Line Amivantamab plus Lazertinib for EGFR NSCLC

20 Aug 2024

Contributed by Lukas

Description: On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of loca...

LCC In Mandarin

16 Aug 2024

Contributed by Lukas

As part of IALC's ongoing series of podcasts in world languages, this podcast brings together four of the leading Chinese lung cancer experts who disc...

IASLC - WCLC 2024 Preview

13 Aug 2024

Contributed by Lukas

Description: In this episode of Lung Cancer Considered, host (and WCLC 2024 Co-Chair) Dr. Narjust Florez previews the upcoming IASLC 2024 World Confer...

IASLC - Spanish Episode Neoadjuvant Therapies In NSCLC

09 Aug 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion in Spanish about perioperative chemotherapy and immunotherap...

Seminal Trial Series: Crizotinib in PROFILE 1001

06 Aug 2024

Contributed by Lukas

Seminal Trial Series: Crizotinib in PROFILE 1001 by IASLC

Lung Cancer Considered in Farsi

02 Aug 2024

Contributed by Lukas

Lung Cancer Considered in Farsi.

LCC In Greek

26 Jul 2024

Contributed by Lukas

LCC In Greek by IASLC

IASLC - Immunotherapy In Driver - Positive NSCLC

26 Jul 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immu...

Clinical Discussion in the Management of Early-Stage NSCLC

23 Jul 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion on the management of early-stage disease, with an eye toward...

LCC: The Management Of CNS Metastases In Driver Negative NSCLC

16 Jul 2024

Contributed by Lukas

Description: Host Dr. Narjust Florez and two esteemed international clinicians discuss the unique characteristics of CNS metastases in patients with ...

Lung Cancer Considered in Romanian

08 Jul 2024

Contributed by Lukas

Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian. Host: Mihael...

The Importance of Waiting for Biomarker Results in NSCLC

02 Jul 2024

Contributed by Lukas

Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results ...

LCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC

20 Jun 2024

Contributed by Lukas

This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian. Guest: Dr. Jessica Menis is a thora...

FDA Approval Of Tarlartamab

18 Jun 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently approved bispecific T-cell engager, tarlatamab, for small cell ...

ASCO 2024 Summary Part 2

14 Jun 2024

Contributed by Lukas

In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cove...

IASLC - ASCO 2024 Summary--Part 1

11 Jun 2024

Contributed by Lukas

Title: ASCO 2024 Highlights Part 1 - Plenary Description: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the ...

Updates in CT Screening for Lung Cancer

04 Jun 2024

Contributed by Lukas

Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer ...

LCC and Smoking Cessation

31 May 2024

Contributed by Lukas

May 31st is World No Tobacco Day and to observe this, Lung Cancer Considered host Dr. Narjust Florez leads a discussion on smoking cessation and how t...

LCC in French Canadian

24 May 2024

Contributed by Lukas

LCC in French Canadian by IASLC

Virtual Tumor Board: PD-L1 Low NSCLC

21 May 2024

Contributed by Lukas

In this virtual tumor board episode, host Dr. Stephen Liu leads a discussion about the management of metastatic, PD-L1 low NSCLC. Dr. Apar Ganti is a...

When two worlds collide: Adenosquamous histology

07 May 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion about adenosquamous cell carcinoma of the lung, from diagnos...

KRAS in NSCLC: Beyond G12C

30 Apr 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung ...

FDA Approval: Adjuvant Alectinib for Resected NSCLC

18 Apr 2024

Contributed by Lukas

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjame...

IASLC DEI Initiative Global Member Survey

16 Apr 2024

Contributed by Lukas

As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus grou...

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

02 Apr 2024

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of ...

ELCC 2024 Highlights

28 Mar 2024

Contributed by Lukas

This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the ...

Emerging Agents In Small Cell Lung Cancer

19 Mar 2024

Contributed by Lukas

Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small ...

Radiopharmaceuticals and Lung Cancer

05 Mar 2024

Contributed by Lukas

This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendoc...

FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC

01 Mar 2024

Contributed by Lukas

Amivantamab Approved by FDA today, March 1! In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of...

Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

29 Feb 2024

Contributed by Lukas

Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the...

From the Basics to Next Line Therapy: ALK + NSCLC

27 Feb 2024

Contributed by Lukas

ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. N...

Best Practice for RET NSCLC

20 Feb 2024

Contributed by Lukas

Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable ...

Biomarkers in Lung Cancer: Barriers to Implementation

16 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found that one-third of oncologists were unaware o...

LCC in Cantonese Chinese: Barriers to Biomarker Testing

16 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evid...

LCC in Mandarin Chinese: Barriers to Biomarker Testing

16 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found one-third of oncologists were unaware of evi...

LCC in French Canadian: Barriers to Biomarker Testing

16 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evid...

LCC in Portuguese: Barriers to Biomarker Testing

16 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evid...

LCC in French: Barriers to Biomarker Testing

16 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evid...

LCC in Japanese: Barriers to Biomarker Testing

14 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evid...

LCC in Spanish: Barriers to Biomarker Testing

10 Feb 2024

Contributed by Lukas

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evid...

The IASLC’s 50th Anniversary and New Strategic Plan

06 Feb 2024

Contributed by Lukas

2024 is the 50th anniversary of the International Association for the Study of Lung Cancer and as we enter this monumental year for IASLC, we do so un...

LCC in Cantonese: Biomarker Testing and EGFR Mutant NSCLC

02 Feb 2024

Contributed by Lukas

Host Dr. Sally Lau, Thoracic Medical Oncologist and Assistant Professor at the New York University Perlmutter Cancer Center, leads a discussion, in Ca...

Meet the New IASLC Chief Scientific Officer Dr. Jennifer King

30 Jan 2024

Contributed by Lukas

Host Dr. Narjust Florez interviews new IASLC Chief Scientific Officer Dr. Jennifer King. In this podcast episode, Dr. King shares her perspective on ...

Lung Cancer in MENA: Clinical and Research Initiatives

26 Jan 2024

Contributed by Lukas

Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as we...

IASLC - Oligometastatic Lung Cancer Part 2

23 Jan 2024

Contributed by Lukas

In Part Two of this Lung Cancer Considered podcast on Oligometastic NSCLC, host Dr. Narjust Florez and guest Dr. Daniel Gomez discuss treatment altern...

Lung Cancer Considered: A Three-Year Review

19 Jan 2024

Contributed by Lukas

Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu host this retrospective look at the podcast, examining how the podcast started, ho...

IASLC Oligometastatic NSCLC

16 Jan 2024

Contributed by Lukas

In Part 1 of a two-part podcast on Oligometastatic lung cancer and the treatment alternatives with local therapy, host Dr. Narjust Florez interviews D...

Maximizing Supportive Care in Lung Cancer

26 Dec 2023

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss the importance of palliative care and psychological support for ...

Lung Cancer in MENA: Clinical and Research Initiatives

22 Dec 2023

Contributed by Lukas

Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as we...

IASLC Chronic Toxicity From Targeted Therapy

19 Dec 2023

Contributed by Lukas

IASLC Chronic Toxicity From Targeted Therapy by IASLC

LCC in Korean: Managing EGFR+ NSCLC

15 Dec 2023

Contributed by Lukas

Lung cancer experts in Korea discuss the unique challenges they face when treating patients with lung cancer with EGFR and non-small cell lung cancer.

New Options for Initial Treatment of EGFR Mutant NSCLC

12 Dec 2023

Contributed by Lukas

In this episode, host Dr. Stephen Liu leads a discussion on the current first-line treatment options for EGFR-mutant non-small cell lung cancer, inclu...

Research from NACLC: Nutrition as Medicine and Lung Cancer Screening

08 Dec 2023

Contributed by Lukas

IASLC Lung Cancer Considered host Dr. Narjust Florez interviews two researchers presenting at the North America Conference on Lung Cancer: Dr. Caroly...

FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor

30 Nov 2023

Contributed by Lukas

Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with ...

FDA Approval: Perioperative Pembrolizumab and KEYNOTE 671

28 Nov 2023

Contributed by Lukas

Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first appr...

It's time to talk about sexual health and lung cancer!

28 Nov 2023

Contributed by Lukas

Sexual health of patients with lung cancer is poorly understood, highly prevalent, and not frequently discussed. However, sexual concerns are common i...

Virtual Tumor Board: Neoadjuvant for Stage III NSCLC

21 Nov 2023

Contributed by Lukas

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the role of neoadjuvant therapy for stage III NSCLC using a virt...

LCC in Dutch: Lung Cancer Care in The Netherlands

17 Nov 2023

Contributed by Lukas

This episode of Lung Cancer Considered covers the current treatment and research landscape in The Netherlands. The episode is recorded in Dutch and i...

AEGEAN and Beyond: Perioperative Immunotherapy for NSCLC

14 Nov 2023

Contributed by Lukas

Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemothera...

Updated IASLC - Hindi

10 Nov 2023

Contributed by Lukas

Title: Lung Cancer Care in India: Approaching a Lung Cancer Diagnosis (Hindi language podcast) The podcast is recorded in Hindi and covers a range of...

FDA Approval: Encorafenib + Binimetinib in BRAF V600E NSCLC

06 Nov 2023

Contributed by Lukas

In this podcast, host Dr. Stephen Liu moderates a discussion a recent FDA approval and a specific molecular subtype of NSCLC. On October 11, 2023, the...

ESMO 2023 Highlights: Early Stage NSCLC, SCLC, Thymic Carcinoma

01 Nov 2023

Contributed by Lukas

Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from Check...

«« ← Prev Page 2 of 4 Next → »»